As of 2025-11-18, the Intrinsic Value of Ascelia Pharma AB (ACE.ST) is -3.50 SEK. This ACE.ST valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.86 SEK, the upside of Ascelia Pharma AB is -222.30%.
Based on its market price of 2.86 SEK and our intrinsic valuation, Ascelia Pharma AB (ACE.ST) is overvalued by 222.30%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.50 - -3.50 | -3.50 | -222.30% |
| P/E | (22.74) - (19.31) | (20.85) | -828.9% |
| DDM - Stable | (10.08) - (327.34) | (168.71) | -5998.9% |
| DDM - Multi | (0.15) - (3.72) | (0.29) | -110.1% |
| Market Cap (mil) | 362.71 |
| Beta | 1.05 |
| Outstanding shares (mil) | 126.82 |
| Enterprise Value (mil) | 291.61 |
| Market risk premium | 5.10% |
| Cost of Equity | 6.53% |
| Cost of Debt | 5.00% |
| WACC | 6.42% |